News|Videos|December 11, 2020

The Future of Sickle Cell Disease and Vaso-Occlusive Crisis

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis. This study was presented at the 62nd ASH Annual Meeting and Exposition.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

$Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists$

The Future of Sickle Cell Disease and Vaso-Occlusive Crisis

Related Content

Bladder Cancer Treatment Is Advancing Faster Than Answers on Sequencing and Toxicity Management

Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer

Study Links H. pylori Exposure to Greater Global Colorectal Cancer Burden

Pharmacist Care Gets BP Patients to Goal Faster, Safer

Osimertinib Keeps Paying Off at 8 Years in Resected EGFR-Mutant NSCLC

Latest CME

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Optimizing Antibody-Drug Conjugate Safety: Pharmacist Strategies for Grading, Monitoring, and Supportive Care

Directions in Oncology Pharmacy® 2026 Southeast

Transforming Generalized Myasthenia Gravis Care: The Evolving Role of Pharmacists in Optimizing Therapy and Long-Term Disease Management

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Access and Formulary Design Considerations for Nonsteroidal Topical Therapies in Dermatology

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Breaking the Transfusion Cycle: A New Era of Independence in Lower-Risk Myelodysplastic Syndromes

Lung Cancer Day of Education 2026

Evolving Hidradenitis Suppurativa Management: Advancements in Treatment and Managed Care Integration Across Patient Populations

AMCP Nexus 2026

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Specialty Pharmacy Day of Education 2026

Directions in Oncology Pharmacy® 2026

Directions in Oncology Pharmacy® 2026 Northeast

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Lymphomas: A Practical Guide for Pharmacists

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Targeting the Complement Cascade: Evolving Strategies in the Management of Complement-Mediated Kidney Diseases

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

New Drug Approvals for 2025 (Pharmacy Technician Credit)

New Oncology Therapy Approvals for 2025 (Pharmacy Technician Credit)

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Lymphoma Day of Education 2026

Shingles Vaccination: Opportunities for Pharmacist Interventions to Provide Patient Education

Evolving Care in IgA Nephropathy: Translating Emerging Evidence Into Care

An Eye on Access: Managed Care Perspectives in Demodex Blepharitis

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Stop and Smell the ROSis: Translating Molecular Results Into Actionable Pharmacy Practice in ROS1-Rearranged NSCLC

2025 SABCS Abstracts to Action: From Data to Decisions in HR+ Breast Cancer Care

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction